Posts

OneDayAdvisor Master Guide: Investing, AI, Technology & Health

Image
OneDayAdvisor Master Guide & Site Index OneDayAdvisor is a research and decision platform covering money, investing, artificial intelligence, technology, healthcare and consumer decision-making. This master guide connects the site's major research areas, tools and practical guides in one place. Last updated:  October 2026  |  Purpose: Master pillar + site index Start here. OneDayAdvisor is designed around a simple idea: better decisions begin with better information. Instead of treating every topic as an isolated article, this site organizes research around the decision a reader is trying to make, the evidence needed to evaluate it, the risks involved and the tools available to help. On this page What Is OneDayAdvisor? Start Here: Choose Your Decision The OneDayAdvisor Knowledge Architecture Money & Investing ...

Best Gold and Silver ETFs for 2026: Investor Guide

Image
Updated October 21, 2026 · Originally published July 2025 · Written by the One Day Advisor Editorial Team · Reviewed by Frank Yap, MBA. Prices and fund data are as of October 16–21, 2026 unless another date is shown. Figures marked “est.” are unconfirmed and should be checked on the issuer’s fund page. Quick Answer As of October 21, 2026, the lowest-cost gold ETFs are IAUM (0.09%) and GLDM (0.10%), IAU (0.25%) offers scale, and GLD (0.40%) is the most liquid. For silver, SLV (0.50%) is the liquid benchmark and SIVR (0.30%) is the cheaper hold. Gold is near $4,127 an ounce, about 23% below its January record, so miner and leveraged funds carry far more risk than bullion funds. Disclosure This article is educational and is not financial or investment advice. Some links to TradingView are affiliate links; we may earn a commission at no cost to ...

GLP-1 Investing Hub 2026: Eli Lilly, Novo Nordisk, Oral Pills, Compounding & Supply-Chain Stocks

Image
By OneDayAdvisor Editorial Team  |  Published: October 14, 2026  |  Last updated: October 16, 2026 Disclosure. This article is educational research, not investment, tax or medical advice. OneDayAdvisor is not a registered investment adviser, and nothing here is a recommendation to buy or sell any security. Company figures come from the sources listed at the end; verify against primary filings before acting. For patient-side guidance on these medicines, see the OneDayMD GLP-1 resource hub . QUICK ANSWER GLP-1 investing in October 2026 has four layers: the two incumbents (Eli Lilly, with Q2 revenue up 48% to $23.0 billion, and Novo Nordisk, with adjusted sales up 7%), the oral-pill race (Wegovy pill vs Foundayo), the compounding crackdown, and picks-and-shovels suppliers. Growth is volume-led while per-patient prices fall, so the key questions are valuation, pipeline timing and policy, not whether demand exists. [1] [4] On this page 1. Market snapshot: the n...